Case Report |
Corresponding author: Oliver Oey ( oliveroey@gmail.com ) © 2023 Oliver Oey, Siaw Sze Tiong, Sze Ling Wong, Suresh Navadgi, Yasir Khan.
This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY 4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Citation:
Oey O, Tiong SS, Wong SL, Navadgi S, Khan Y (2023) Triple synchronous malignancies of the stomach, bladder and thyroid in a previously treated prostate cancer patient: A Case Report. Folia Medica 65(4): 693-698. https://doi.org/10.3897/folmed.65.e96012
|
Cancers that develop within six months of the first primary cancer are referred to as synchronous malignancies. These malignancies are difficult to diagnose and treat, with treatment primarily based on case reports.
We report here the case of a 51-year-old male with prior history of prostate cancer who presented with haematuria to the general practice. A CT pyelogram showed left bladder wall lesion that was further investigated with cystoscopy and biopsy confirmed as muscle-invasive urothelial carcinoma. Incidentally, two perigastric nodes and hepatic lesions were noted on CT. FDG-PET revealed high-grade uptake in the right lobe of thyroid gland and cervical nodes that was biopsy proven as papillary thyroid carcinoma. Subsequently, gastroscopy and a biopsy of the gastric lesion confirmed a gastric neuroendocrine tumour. The patient underwent chemoradiotherapy, total thyroidectomy, and commenced somatostatin analogue for treatment of urothelial carcinoma, papillary thyroid carcinoma, and neuroendocrine tumour, respectively.
The diagnosis and treatment of synchronous malignancies is complex. A multidisciplinary team approach is required to improve treatment outcomes.
synchronous malidnancies, neuroendocrine cancer, thyroid cancer, bladder cancer, case report
Synchronous malignancies (SM) refer to two or more independent primary cancers where the second, third, and subsequent cancer arise within 6 months of the primary cancer.[
Some SM are known to occur in specific types of cancers as a consequence of inheritance of cancer predisposition syndrome.[
A 51-year-old male of Italian ethnicity presented to the general practice with a 4-day history of haematuria and lower urinary tract symptoms, including dysuria and increased urinary frequency. He was otherwise well, with no abdominal pain, nausea, vomiting, bowel habit alterations, weight loss, fever, or night sweats. A review of other systems was unremarkable. He had a prior history of locally advanced prostate cancer diagnosed at age 42, for which he underwent a robotic prostatectomy and had since then been in remission. The patient works as a fire system tester; however, no significant exposure to carcinogenic chemicals was noted. He had a 30 pack-year smoking history, no other significant co-morbidities, and occasionally drinks alcohol. In terms of family history, the patient’s mother had breast cancer and brother had prostate cancer, both diagnosed above the age of 50.
A CT pyelogram showed a hepatic lesion and a left bladder wall lesion that was further investigated by the Urology team one month later with a cystoscopy and biopsy of the lesion, which was histologically confirmed as T2 high-grade muscle-invasive UC with lymphovascular invasion. A CT scan incidentally noted two perigastric lymph nodes measuring 1 cm each, along with hepatic lesions. A fluorodeoxyglucose (FDG)-PET scan was subsequently performed, revealing high-grade uptake in the upper pole of the right lobe of the thyroid gland, highly suspicious of another primary cancer (Fig.
FDG-PET scan revealing high-grade uptake in the upper pole of right lobe of thyroid gland.
Neuroendocrine tumour grade 3 of primary gastrointestinal tract origin. H&E stained sections depicting tumour cells with stippled chromatin and lack of mitotic activity.
Neuroendocrine tumour grade 3 of primary gastrointestinal tract origin. Synaptophysin immunostain showing diffuse cytoplasmic positivity in tumour cells.
Gallium octreotide PET scan showing significant uptake in the primary gastric mass as well as a segment II and IV liver metastasis, consistent with metastatic neuroendocrine tumour.
The patient was discussed in both urology and upper gastrointestinal multidisciplinary team (MDT) meetings at a tertiary hospital and the consensus was to proceed with curative-intent radical chemoradiotherapy with 5-flurouracil and mitomycin for UC, total thyroidectomy with right modified radical neck dissection for his PTC and commence a somatostatin analogue (SSA) for treatment of his NET with consideration of surgery down the track if the tumour responds positively to SSA such that R0 resection can be achieved or trial of peptide receptor radionuclide therapy (PRRT) in the event of lanreotide failure.
Upon completion of radical chemoradiotherapy for urothelial carcinoma of the bladder, the patient had radiological and clinical complete response on FDG-PET and three months later remained in remission. Gastric NET was complicated by perforation of the tumour which was managed conservatively with intravenous antibiotics. Having completed three cycles of lanreotide injection, the patient demonstrated a partial treatment response with reduction in size of gastric, liver, and pancreas lesion on gallium octreotide PET scan. Therefore, surgery may be offered in the future as planned if patient is keen. Finally, with regards to his PTC, upon undergoing a total thyroidectomy, the cancer was found to be locally advanced with lymphovascular invasion (T2N1bM0, stage I), prompting referral to the Nuclear Medicine Team for adjuvant radioactive iodine therapy. Thyroid surgery was also complicated by a mild neck seroma which did not require any surgical intervention.
Nine months since the diagnosis of his SM, the patient remained well while maintaining a good quality of life. With the support of his friends and partner, he coped well with the complex treatment of his SM and is adamant that he would pursue all recommended treatment in the future intended to prolong life. His cancer surveillance regimen include 3 monthly FDG-PET scan for surveillance of his bladder cancer, 3 monthly gallium octreotide PET scan for his NET, and 6 monthly ultrasound of the thyroid for his thyroid cancer. He has also been tested by Genetic Services of Western Australia for genetic abnormalities or familial syndromes and awaiting results.
We presented a unique case of a 51-year-old male with SM of gastric NET, PTC, and UC of the bladder. To the best of our knowledge, this is the first case of its kind to be reported in the literature, with no notable cancer syndrome plausibly explaining this spectrum of malignancies. While SM of NET and other primary malignancies used to be regarded as an exotic event, a recent study by Parra-Medina et al.[
In recent years, the availability of sophisticated imaging methods such as PET-CT scans and whole-body MRI implies that it is not uncommon for incidental lesions that would have not been picked up by conventional CT scan to be detected. In a series of 200 patients with oesophageal cancer who had PET-CT scan, 17% of patients had SM with cancers in various organs from stomach, colon to lung.[
Treatment of patients with SM is complex and clinicians often encounter a therapeutic dilemma. Discussion in a multidisciplinary team involving at least medical oncologists, surgeons, radiation oncologists, radiologists, and pathologists is required to maximise treatment success and outcomes.[
In our case, following the diagnosis of SM, the patient was adamant that he wanted to pursue treatment with curative intent. Following the diagnosis of muscle invasive bladder cancer, the patient elected for chemoradiotherapy with curative intent. The patient completed concurrent chemoradiotherapy with mitomycin and 5-flurouracil and 55 Gy in 20 fractions of definitive radiotherapy and was declared in remission. A multidisciplinary team (MDT) convened for discussion of the patient’s thyroid cancer and NET came to a consensus that the patient should proceed with a curative treatment for thyroid cancer - total thyroidectomy with right modified radical neck dissection - and commence lanreotide injection for his NET, which the patient agreed to. The decision for the latter was based on the fact that the patient presented with advanced disease, making it impossible to achieve R0 resection, and limited evidence of the role of debulking surgery for NET relative to treatment with lanreotide.[
Limitations on this case report include the unavailability of genomic data at the time of writing to explain the spectrum of SM and the short follow-up time of the patient since first diagnosed. However, our report provides valuable insight into the management of a rare spectrum of SM – the first of its kind to be reported in the literature.
In conclusion, SM can be difficult to diagnose and treat. A multidisciplinary team management approach should be adopted to optimise treatment for patients with SM, with treatment tailored to align with patients’ goals. As patients with SM are generally excluded from clinical trials, it is unlikely that randomized control trials will be conducted in the future to inform best practice for management of SM. However, with the advancement of tumour profiling, tumour samples from the SM should be genomically profiled to optimise treatment strategy and improve patient outcomes.
The authors have no support to report.
The authors have no funding to report.
The authors have declared that no competing interests exist.